Roles of Some Non-classic Biomarkers in Pediatric Pneumonia

The current work aims to:Measure the levels of Neutrophil CD64 Receptor, Monocyte Human Leukocyte Antigen-DR (mHLA-DR), and Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) in children suffering from pneumonia.Compare these levels to their levels in healthy control children.Analyze the cut-off point, sensitivity, specificity, and area under the ROC curve of these biomarkers to test their abilities to early differentiate children with pneumonia from healthy control children.Conclude or reject their possible use as diagnostic and/or prognostic markers in pediatric pneumonia.

Inclusion Criteria:Children more than one month and till age of 5 yearsClinical diagnosis of CAP.Exclusion Criteria:1) All pediatric patients with comorbidities and diagnosed with CAP as: severe sepsis& localized infections e.g., endocarditis, empyema& autoimmune diseases& liver cirrhosis& children receiving immunosuppressive therapy.